Oryzon Genomics SA (ORYZF) Stock Price, News & Analysis
Price Move History
- Daily moves over 5%
- 3 17 sessions, October 3, 2025 to September 30, 2026
- Largest daily move
- +9.3% close of May 19, 2026
- 1-month change
- -5.3% closing prices, August 28, 2026 to September 30, 2026
Company Description
Oryzon Genomics SA (OTC: ORYZF) is classified in the biotechnology industry within the Healthcare sector and carries a market capitalization of $253.9M.
ORYZF declined 5.3% in the month to September 30, 2026. The last closing price was $3.10.
This page collects what Stock Titan holds for ORYZF, including price data, latest news, and short interest trends.
Stock Performance
Oryzon Genomics SA (ORYZF) closed at $3.10 on September 30, 2026. In the month to September 30, 2026, the price lost 5.3%.
ORYZF Metrics & Rankings
Price returns through September 30, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Oryzon Genomics SA has 10 recent news articles. Of the recent coverage, 0 articles coincided with positive price movement and 1 with negative movement. Key topics include fda approval, clinical trial. View all ORYZF news →
SEC Filings
Short Interest History
Short interest in Oryzon Genomics SA (ORYZF) currently stands at 30.0 thousand shares, up 513.5% from the previous reporting period, representing 0.0% of the float. Since November 2025, short interest has increased by 81102.7%.
Days to Cover History
Days to cover for Oryzon Genomics SA (ORYZF) currently stands at 8.1 days, up 607% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 99.2%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.
ORYZF Company Profile & Sector Positioning
Oryzon Genomics SA (ORYZF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.
Investors comparing ORYZF often look at related companies in the same sector, including Clinuvel Pharms (CLVLF), Northwest Biothrputcs Inc (NWBO), Starpharma Holdings (SPHRY), BetterLife Pharma Inc (BETRF), and Vaxart Inc (VXRT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate ORYZF's relative position within its industry.